Ethos was originally founded in August 2000 and its
mission is to deliver the very best natural health products collected
from all four corners of the globe.
Macular Degeneration (AMD, Age-related macular
degeneration) is most common in people over 50, but can appear as early
as age 40. As life expectancy increases, the disease is becoming a
significant problem with thousands of people being diagnosed each year.
Millions of older people experience blurred or distorted vision from
macular degeneration, which can put an end to activities such as reading
and driving. In fact, age-related macular degeneration (AMD) affects
one in three people over the age of 75 and is the leading cause of
irreversible blindness among adults.
Worldwide, glaucoma is the second leading cause of blindness; cataracts being the first. glaucoma treatment eye drops has been nicknamed the "sneak thief of sight" because the loss of visual field often occurs gradually, over a long period of time, and may only be recognised when it is already quite advanced. Therefore it is important to have eye examinations at regular intervals where a ‘contrast sensitivity test’ should be performed along with a field test to measure visual loss.
Ethos bright eyes drops were first introduced to Europe by the world-leading biochemist Professor Steven Charles Gallant who had studied the many different effects and benefits of L-Carnosine ever since he first graduated.
His colleague, Professor Alexander Boldyrev in Moscow, had first discovered the positive effects that N-Acetyl-Carnosine and NAC eye drops had on dissolving cataracts in 1988. Steven said that when his father first discovered that he had cataracts he really didn't relish the thought of going under the knife and having the operation so Steven tried to procure some of the drops for him but, at that time, they unfortunately weren't readily available.
